Status:
UNKNOWN
Comparative Efficacy of Rebamipide Gargle And Benzydamine HCL Gargle in Prevention and Management of Chemo- and Radio-therapy-induced Oral Mucositis
Lead Sponsor:
Cairo University
Conditions:
Oral Mucositis
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
evaluate preventive and therapeutic effects of Rebamipide gargle on reducing incidence of oral mucositis in comparison with benzydamine HCL mouthwash.
Detailed Description
Oral mucositis is a common and potentially dangerous complication of anticancer treatment. Inflammation and ulcerations of the oral mucosa make swallowing and, thereby, eating and drinking, difficult ...
Eligibility Criteria
Inclusion
- Male and female patients with head and neck cancer and who will be prescribed radiotherapy at least 60 Gy (Roopashri et al., 2011).
- Patients who will sign an informed consent,
- Patients older than 18 years of age,
- Patients having normal renal and liver functions
Exclusion
- • . Use of dentures, or having any source of infection in the mouth.
- Allergy to rebamipide or benzydamine hydrochloride(Nithin et al., 2018) .
Key Trial Info
Start Date :
December 26 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 15 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04685395
Start Date
December 26 2019
End Date
September 15 2021
Last Update
December 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kasr El-Einy Center of Radiation Oncology and Nuclear Medicine
Cairo, Egypt